Canadian liver journal最新文献

{"title":"Commentary on Vincelette et al.","authors":"Arafat Hassan Tariq, Mirha Imran Khan, Waqar Ahmad Alvi","doi":"10.3138/canlivj-2024-0059","DOIUrl":"10.3138/canlivj-2024-0059","url":null,"abstract":"","PeriodicalId":510884,"journal":{"name":"Canadian liver journal","volume":"8 2","pages":"272-273"},"PeriodicalIF":0.9,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12269188/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144661630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to Commentary on Kehar et al.","authors":"Vikrant Sood, Mohit Kehar","doi":"10.3138/canlivj-2024-0057","DOIUrl":"10.3138/canlivj-2024-0057","url":null,"abstract":"","PeriodicalId":510884,"journal":{"name":"Canadian liver journal","volume":"8 2","pages":"270-271"},"PeriodicalIF":0.9,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12269298/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144661643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to Commentary on Vincelette et al.","authors":"Christian Vincelette, François Martin Carrier","doi":"10.3138/canlivj-2024-0061","DOIUrl":"10.3138/canlivj-2024-0061","url":null,"abstract":"","PeriodicalId":510884,"journal":{"name":"Canadian liver journal","volume":"8 2","pages":"274-275"},"PeriodicalIF":0.9,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12269236/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144661644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Commentary on Kehar et al.","authors":"Huzafa Ali, Munaiba Ahmad, Mahfuja Jahan Ima","doi":"10.3138/canlivj-2024-0051","DOIUrl":"10.3138/canlivj-2024-0051","url":null,"abstract":"","PeriodicalId":510884,"journal":{"name":"Canadian liver journal","volume":"8 2","pages":"268-269"},"PeriodicalIF":0.9,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12269311/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144661629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PPAR Agonists: The Next Innovation in Hepatology.","authors":"Natasha Chandok, Eric M Yoshida","doi":"10.3138/canlivj-2025-0021","DOIUrl":"https://doi.org/10.3138/canlivj-2025-0021","url":null,"abstract":"","PeriodicalId":510884,"journal":{"name":"Canadian liver journal","volume":"8 2","pages":"267"},"PeriodicalIF":0.9,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12269168/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144661640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Management of Chronic Hepatitis B: 2025 Guidelines Update from the Canadian Association for the Study of the Liver and Association of Medical Microbiology and Infectious Disease Canada.","authors":"Carla Osiowy, Fernando Alvarez, Carla S Coffin, Curtis L Cooper, Scott K Fung, Hin Hin Ko, Sébastien Poulin, Jennifer van Gennip","doi":"10.3138/canlivj-2025-0012-e","DOIUrl":"10.3138/canlivj-2025-0012-e","url":null,"abstract":"<p><p>Chronic hepatitis B virus (HBV) infection poses significant public health challenges in Canada, particularly among newcomers from regions with high HBV prevalence. In alignment with the World Health Organization's goal of HBV elimination by 2030, this 2025 guidelines update-developed jointly by the Canadian Association for the Study of the Liver (CASL) and the Association of Medical Microbiology and Infectious Disease (AMMI) Canada-presents recommendations for universal adult HBV screening, vaccination, laboratory assessment, and treatment. These guidelines emphasize patient-centred care, early diagnosis, and expanded antiviral treatment, including for individuals in the indeterminate or <i>grey zone</i> and special populations such as pregnant individuals, children, and those coinfected with HIV, hepatitis C, or hepatitis D. Notably, the guidelines recommend reflex HDV testing and routine use of quantitative HBsAg to support management decisions. These evidence-based recommendations are informed by expert consensus, recent literature, and international standards, with the aim of improving outcomes, reducing stigma, and informing future policy and research priorities.</p>","PeriodicalId":510884,"journal":{"name":"Canadian liver journal","volume":"8 2","pages":"368-440"},"PeriodicalIF":0.9,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12269321/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144661648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and Predicting Factors of Caregiver Burden in Cirrhotic Patients.","authors":"Carmen Ching, Nicole Wiebe, Julie Zhu","doi":"10.3138/canlivj-2025-0013","DOIUrl":"10.3138/canlivj-2025-0013","url":null,"abstract":"<p><strong>Background: </strong>Cirrhosis is a major cause of morbidity and mortality. Caregivers of cirrhotic patients provide significant support related to disease manifestations and complications. This scoping review aims to identify the prevalence of caregiver burden among patients with cirrhosis and to identify patient and caregiver factors that predict caregiver burden in patients with cirrhosis.</p><p><strong>Methods: </strong>A literature search was conducted using MEDLINE, EMBASE, CINAHL, and Web of Science to identify studies for inclusion. Screening and data extraction were performed using Covidence systematic review software (Veritas Health Innovation, Melbourne, Australia).</p><p><strong>Results: </strong>604 articles were identified, and 15 were included in the review. Caregivers were predominantly female and spouses of the patient. The average age of patients varied between 41.2 and 57.2 (SD 10.3 to 12.5). The most common cirrhotic aetiologies were alcohol-related, viral hepatitis-related, and metabolic-related aetiologies. The most used survey tools to assess burden were the Zarit Burden Interview (ZBI) score, Short Form-36 Health Survey (SF-36), and Beck Depression/Anxiety Inventory (BDI or BAI). Patient factors contributing toward caregiver burden included prior hepatic encephalopathy (HE), alcohol use, and high Model for End-Stage Liver Disease (MELD) scores. Caregiver factors that contribute toward caregiver burden included poor perceived social supports, low and disrupted income, and being the spouse of the patient.</p><p><strong>Conclusions: </strong>Several patient and caregiver factors contribute to caregiver burden, and greater levels of burden may affect multiple aspects of a caregiver's life, potentially worsening patient outcomes. A multidisciplinary approach is critical to alleviate caregiver burnout and optimize the overall care for a patient with cirrhosis.</p>","PeriodicalId":510884,"journal":{"name":"Canadian liver journal","volume":"8 2","pages":"355-367"},"PeriodicalIF":0.9,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12269208/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144661642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of New Direct-Acting Antiviral Therapy on the Prevalence and Undiagnosed Proportion of Chronic Hepatitis C Infection in Alberta: A Model-Based Analysis.","authors":"Farinaz Forouzannia, Diedron Lewis, Nkiruka Eze, Fiona Clement, William W L Wong","doi":"10.3138/canlivj-2024-0062","DOIUrl":"10.3138/canlivj-2024-0062","url":null,"abstract":"<p><strong>Background: </strong>Understanding the impact of wider access to treatment on chronic hepatitis C (CHC) prevalence and the undiagnosed CHC proportion is important to achieving the World Health Organization's 2030 elimination targets. This research aimed to: (1) estimate the CHC prevalence and undiagnosed rates in Alberta, Canada; and (2) explore the impact of new direct-acting antiviral therapy on these rates since its introduction in 2014.</p><p><strong>Methods: </strong>This study adopted a two-step approach to estimate CHC prevalence and undiagnosed rates. This involved a population-based retrospective analysis of health administrative data for Alberta from 2002 to 2018 to generate CHC-related events for three birth cohorts: individuals born before 1945, individuals born between 1945 and 1965, and individuals born after 1965. A back-calculation method was employed to obtain historical prevalence and incidence estimates.</p><p><strong>Results: </strong>After the introduction of direct-acting antiviral treatment in 2014, the mean prevalence of CHC over all the birth cohorts fell by approximately 6.5% from 1.23% (95% CI: 0.97%-1.5%) to 1.15% (95% CI: 0.91%-1.45%) between 2015 and 2018. Similar trends were estimated for the 1945-1965 and the >1965 birth cohorts over the same period. Likewise, the mean proportion of undiagnosed CHC infections over all the birth cohorts fell by approximately 8.25% from 39.36% (95% CI: 30.08%-48.48%) to 36.36% (95% CI: 27.49%-45.31%) over the same period. A similar trend was experienced in all three birth cohorts.</p><p><strong>Conclusions: </strong>This is the first study to estimate CHC prevalence and undiagnosed proportions in Alberta using provincial health administrative data. These results could provide vital evidence to guide decisions about current and future hepatitis C virus strategies and help achieve the World Health Organization goal of eliminating hepatitis C in Canada by 2030.</p>","PeriodicalId":510884,"journal":{"name":"Canadian liver journal","volume":"8 2","pages":"344-354"},"PeriodicalIF":0.9,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12269285/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144661647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Telemedicine Approaches for Patients with Cirrhosis, Including Vulnerable Populations: A Narrative Review.","authors":"Man Ting Kristina Yau, Cynthia Tsien","doi":"10.3138/canlivj-2025-0008","DOIUrl":"10.3138/canlivj-2025-0008","url":null,"abstract":"<p><strong>Background: </strong>The COVID-19 pandemic accelerated the adoption of telemedicine in health care. However, telemedicine in cirrhosis care remains underexplored. In particular, patients with alcohol use disorder (AUD) and hepatitis C virus (HCV) may be overrepresented among vulnerable populations, but have limited access to telemedicine.</p><p><strong>Method: </strong>We performed a literature review on telemedicine approaches for patients with cirrhosis as well as patients with AUD and HCV with or without cirrhosis. Peer-reviewed studies involving direct patient-physician interactions were searched on PubMed and Google Scholar. Keywords used included <i>cirrhosis, AUD, HCV,</i> and <i>telemedicine.</i> Abstracts were screened. Full texts were reviewed.</p><p><strong>Results: </strong>Among patients with cirrhosis, videoconferencing at satellite sites shortened the time from liver transplant referral to evaluation and listing. Telephone calls were less effective, especially for those with decompensated cirrhosis. Among patients with AUD, videoconferencing at satellite sites was effective, with patients being five times more likely to be prescribed medications. Treatment programs involving videoconferencing and telephone calls demonstrated retention rates above 50%. Among patients with HCV, videoconferencing was effective, with high (>90%) sustained virological response rates. Across all approaches, concerns raised included audiovisual quality, patient privacy, and licensing restrictions.</p><p><strong>Conclusion: </strong>Videoconferencing at satellite sites is most promising if audiovisual quality and other barriers are optimized. Telemedicine may not be appropriate for management of decompensated cirrhosis.</p>","PeriodicalId":510884,"journal":{"name":"Canadian liver journal","volume":"8 2","pages":"329-343"},"PeriodicalIF":0.9,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12269323/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144661645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and Biochemical Features of Diagnosed and Undiagnosed Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease.","authors":"Gerald Yosel Minuk, Mona Baseri, Eleonora Bakalets, Manna Zhang, Julia Uhanova","doi":"10.3138/canlivj-2025-0053","DOIUrl":"10.3138/canlivj-2025-0053","url":null,"abstract":"<p><strong>Background: </strong>The majority of the world's metabolic dysfunction-associated steatotic liver disease (MASLD) patient population remain undiagnosed. Whether the clinical and biochemical features of these individuals resemble those with an established diagnosis of MASLD remains to be determined. The aim of this study was to document and compare the demographics, associated metabolic comorbidities, liver biochemistry, and non-invasive markers of hepatic fibrosis and portal hypertension in diagnosed versus undiagnosed MASLD patients.</p><p><strong>Methods: </strong>The two study cohorts consisted of 3,101 MASLD patients attending a tertiary care centre (diagnosed) and 408 individuals with MASLD identified as a result of volunteering in a community-based MASLD screening clinic (undiagnosed).</p><p><strong>Results: </strong>Diagnosed MASLD patients were younger (51±14 vs. 54±13 years, <i>p</i> <0.00001), more often male (50% vs. 34%, <i>p</i> <0.00001), and diabetic (40% vs. 17%, <i>p</i> <0.00001) but less often dyslipidemic (29% vs. 46%, <i>p</i> <0.00001). BMIs were similar in the two cohorts. The prevalence and extent of liver transaminases (ALT and AST) and function test (albumin, bilirubin, and INR values) abnormalities were greater in diagnosed MASLD patients as were non-invasive determinants of hepatic fibrosis and portal hypertension (higher FIB-4 values and lower platelet counts, respectively).</p><p><strong>Conclusions: </strong>The demographics, metabolic co-morbidities, and severity of liver disease differ in diagnosed versus undiagnosed MASLD patients.</p>","PeriodicalId":510884,"journal":{"name":"Canadian liver journal","volume":"8 2","pages":"322-328"},"PeriodicalIF":0.9,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12269264/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144661628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}